LAS VEGAS--(BW HealthWire)--April 13, 1999--Steroidogenesis
Inhibitors International (OTC BB:STGI) today announced that it will be
a featured company on Talk-Stock Radio (http://www.talk-stock.com)
with host Kenneth Coleman interviewing Dr. Alfred T. Sapse, President,
and Dr. Janet Greeson, Executive Vice President on April 15, 1999 at
9:00 p.m. EDT (6:00 p.m. PDT) in the Talk-Stock Radio room.
     Talk-Stock.com is an on-line forum that broadcasts outstanding
companies and investment opportunities to a worldwide audience with
its broadcasts later translated into German, Spanish and Chinese.
     STGI is a pharmaceutical R&D Corporation, engaged in the
development of anticortisol drugs to be used in diseases/conditions
associated with elevated levels of the immunosuppressive hormone
cortisol.  STGI's flagship anticortisol drug, ANTICORT, has been
approved by the FDA to be clinically tested in an HIV population -- a
condition often associated with "high cortisol" that is apparently
playing a major role in the destruction of the immune system as
encountered in HIV+ and AIDS.
     This release may include "forward-looking statements" within the
meaning of section 27A of the Securities Act of 1933 and Section 21E
of the Securities Act of 1934. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable it can give no assurance that such expectations will prove
correct. This is neither an offer to buy or sell a security. This
release is for informational purposes only, from sources deemed to be
reliable. For more information visit our World Wide Web page at
www.anticort.com.

     CONTACT: Steroidogenesis
              Janet Greeson, 702/735-7001
              or
              Performance Strategies
              Richard L. Brown/Chuck Jordan, 303/471-5943
              or
              H.L. Lanzet Inc.
              Herbert Lanzet/DeeDee Lanzet, 212/687-0061